EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin Mitigates Doxorubicin-Induced Cardiotoxicity in Rats: Electrocardiographic, Biochemical, and Histopathological Evidence

Iacob-Daniel Goje iD, Valentin Laurențiu Ordodi, Greta-Ionela Goje iD, Florina Maria Bojin iD, Andrei-Dragoș Crăciun iD, Daniela Crîsnic, Mihnea Derban, Andreea Severina Barbulescu, Valentina Gabriela Ciobotaru, Virgil Păunescu, Daniel-Florin Lighezan

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27073090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Iacob-Daniel Goje und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Semiology I, "Victor Babeș" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: Doxorubicin, Glucosides, Benzhydryl Compounds, Cardiotoxicity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babeș University of Medicine and Pharmacy Timișoara, “VICTOR BABES” University of Medicine and Pharmacy, Timisoara https://ror.org/00afdp487.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) is a widely used anthracycline, but its clinical use is limited by dose-dependent cardiotoxicity. This experimental study evaluated the cardioprotective potential of empagliflozin (EMPA) against DOX-induced cardiotoxicity. Thirty healthy adult rats were randomized into five groups (n = 6): control (group I), EMPA (group II), EMPA + DOX (group III), DOX (group IV), and EMPA-preconditioning + DOX (group V). EMPA was administered orally at 10 mg/kg/day, either concomitantly with DOX or as a 14-day preconditioning course. Cumulative DOX exposure reached 15 mg/kg to establish a reproducible cardiotoxicity model. Serial electrocardiograms (ECGs) were recorded, blood samples were collected, and hearts were harvested for detailed histopathological analysis. Compared with the control group, group IV demonstrated significant QT/QTc prolongation and repolarization abnormalities, marked troponin elevation, and characteristic histological lesions, including cardiomyocyte vacuolization, loss of striations, diffuse inflammation, myocyte atrophy, and increased fibrosis. In groups receiving EMPA with DOX exposure (groups III and V), ECG changes were attenuated, troponin elevation was lower, and structural myocardial damage was substantially reduced, with better preservation of cardiomyocyte architecture and less fibrosis. These results suggest that EMPA provides significant cardioprotection against DOX-induced cardiotoxicity in rats, supporting further investigation of SGLT2 inhibitors in cardio-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinGlucosidesBenzhydryl CompoundsCardiotoxicityCardiotonic AgentsSodium-Glucose Transporter 2 InhibitorsAnimalsElectrocardiographyRatsMaleMyocardiumMyocytes, CardiacHeart

Stichwörter der Autor:innen

SGLT2 inhibitorsanthracyclinescardio-oncologycardiotoxicitydoxorubicin

Substanzen

DoxorubicinGlucosidesempagliflozinBenzhydryl CompoundsCardiotonic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medical Semiology I, "Victor Babeș" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.
  • Advanced Cardiology and Hemostaseology Research Center, "Victor Babeș" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.
  • Immuno-Physiology and Biotechnologies Center, Department of Functional Sciences, "Victor Babeș" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.
  • Faculty of Industrial Chemistry and Environmental Engineering, "Politehnica" University Timisoara, No. 2 Victoriei Square, 300006 Timisoara, Romania.
  • OncoGen-Center for Gene and Cell Therapies in Cancer Treatment, Clinical Emergency County Hospital "Pius Brinzeu" Timisoara, No. 156, Liviu Rebreanu, 300723 Timisoara, Romania.
  • Department I of Nursing, University Clinic of Clinical Skills, "Victor Babeș" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.

ORCID-Profile: Iacob-Daniel Goje, Greta-Ionela Goje, Florina Maria Bojin, Andrei-Dragoș Crăciun

Förderung

  • Victor Babeș University of Medicine and Pharmacy Timișoara
  • “VICTOR BABES” University of Medicine and Pharmacy, Timisoara https://ror.org/00afdp487

Zitieren

APA

Goje, I. D., Ordodi, V. L., Goje, G. I., Bojin, F. M., Crăciun, A. D., Crîsnic, D., Derban, M., Barbulescu, A. S., Ciobotaru, V. G., Păunescu, V., & Lighezan, D. F. (2026). Empagliflozin Mitigates Doxorubicin-Induced Cardiotoxicity in Rats: Electrocardiographic, Biochemical, and Histopathological Evidence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073090

Vancouver

Goje ID, Ordodi VL, Goje GI, Bojin FM, Crăciun AD, Crîsnic D, et al. Empagliflozin Mitigates Doxorubicin-Induced Cardiotoxicity in Rats: Electrocardiographic, Biochemical, and Histopathological Evidence. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073090

BibTeX
@article{Goje2026,
  author = {Goje, Iacob-Daniel and Ordodi, Valentin Laurențiu and Goje, Greta-Ionela and Bojin, Florina Maria and Crăciun, Andrei-Dragoș and Crîsnic, Daniela and Derban, Mihnea and Barbulescu, Andreea Severina and Ciobotaru, Valentina Gabriela and Păunescu, Virgil and Lighezan, Daniel-Florin},
  title = {Empagliflozin Mitigates Doxorubicin-Induced Cardiotoxicity in Rats: Electrocardiographic, Biochemical, and Histopathological Evidence},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27073090}
}
Kostenlos starten →